There is no single “best” RSV vaccine among Arexvy, Abrysvo, and mResvia. Each is approved for older adults, and the right choice depends on your age, health conditions, and which one is actually available where you get vaccinated. All three reduce the risk of serious RSV illness, and no major study has shown one to be clearly superior to the others in older adults.
That answer may feel unsatisfying if you were hoping for a clear winner. But the honest picture is more useful: these vaccines differ in ways that matter for specific people, and understanding those differences helps you and your clinician make a sensible decision.
What Is RSV and Why Does It Matter After Age 60?
Respiratory syncytial virus is a common virus that most people catch many times across a lifetime. In healthy children and younger adults, it usually causes cold-like symptoms. In older adults, it can be far more serious.
RSV is a leading cause of lower respiratory tract infection in older adults. It can lead to pneumonia, hospitalization, and in some cases death. Adults with chronic heart or lung disease, weakened immune systems, or frailty face the highest risk. The risk climbs with age, largely because the immune system weakens over time.
For decades, there was no vaccine. That changed in 2023, when the first RSV vaccines for older adults were approved in the United States. A third option followed. That is why this question exists now.
Which RSV Vaccines Are Approved for Older Adults?
Three vaccines are approved for adults aged 60 and older in the US: Arexvy, Abrysvo, and mResvia. They use different technologies, which is the main reason they are not identical.
- Arexvy is a protein-based vaccine that includes an adjuvant — an ingredient that boosts the immune response.
- Abrysvo is also protein-based, but it is adjuvant-free and is additionally approved for use in pregnancy to protect newborns.
- mResvia is an mRNA vaccine, built with the same underlying technology platform used in some COVID-19 vaccines.
All three target the same virus protein. The difference lies in how the immune system is prompted to respond and in the populations each is cleared for.
Which RSV Vaccine Is Better — Arexvy, Abrysvo, or mResvia?
No head-to-head trial has directly compared all three vaccines against each other in older adults. That means any claim that one is “better” overall is not supported by direct comparative evidence.
What we do have is separate trials for each vaccine, each showing that the vaccine reduced the risk of RSV-related lower respiratory tract disease compared with placebo. The trials were run in different populations, at different times, and with slightly different endpoints. Comparing results across separate trials is unreliable — a common trap in how vaccine data gets reported.
So the accurate statement is this: all three reduce RSV illness in older adults, and the evidence supports each one on its own terms. The choice usually comes down to eligibility, availability, and individual health factors rather than a clear efficacy ranking.
How Do the Three Vaccines Differ in Practical Terms?
The differences that matter most in a clinic are age eligibility, approved populations, and how the vaccine is made.
| Vaccine | Type | Adjuvant | Approved for pregnancy |
|---|---|---|---|
| Arexvy | Protein-based | Yes | No |
| Abrysvo | Protein-based | No | Yes |
| mResvia | mRNA | No | No |
The age thresholds have shifted since these vaccines first launched. The original approval was for adults 60 and older. Guidance has since expanded, and the exact age recommendations have been updated more than once. Because these thresholds can change, the most reliable source is current guidance from public health authorities or your clinician — not a fixed number you read somewhere months ago.
Abrysvo stands apart because it is the only one of the three approved for use during pregnancy, where the goal is to protect the newborn. That is a different use case from older-adult vaccination and is not a reason to consider it “stronger” for adults.
Does the Type of Vaccine Change How Well It Works?
Vaccine technology affects how the immune system is stimulated, but it does not automatically translate into better real-world protection. A protein vaccine with an adjuvant and an mRNA vaccine can both produce strong immune responses through different routes.
It is tempting to assume the newer technology is more effective. That assumption is not supported by direct comparisons in older adults. Each platform has its own trial data, and each met the bar for approval. Biological plausibility — the idea that one design “should” work better — is not the same as demonstrated clinical benefit.
What matters more for an individual is often simpler: whether the vaccine is available, whether it fits their health situation, and whether they actually get it.
Who Should Get an RSV Vaccine?
RSV vaccination is recommended for older adults, with the strongest case for those at higher risk of severe illness. That includes adults with chronic heart or lung conditions, weakened immune systems, or significant frailty, and generally those in the older age brackets.
For healthier adults at the younger end of the eligible range, the decision is more of a conversation. The benefit is real but smaller when baseline risk is lower. Some clinicians recommend it broadly across the eligible age group; others focus on higher-risk patients. Both approaches reflect the same evidence viewed through different lenses.
This is genuinely a case where talking with your clinician is worth the time. Your personal risk profile shapes the answer more than any general ranking of the three vaccines.
What About Side Effects?
The most common side effects across all three vaccines are similar to those of many adult vaccines: pain at the injection site, fatigue, muscle aches, headache, and sometimes fever. These usually resolve within a few days.
Serious adverse events were uncommon in the trials for all three vaccines. As with any newly licensed vaccine, monitoring continues after approval, and that surveillance is how rare signals get detected over time. If you have had a severe reaction to a vaccine before, tell your clinician before getting another.
Can You Get More Than One, or Switch Between Them?
There is no established reason to receive more than one type of RSV vaccine, and no evidence supporting a strategy of mixing them. Current guidance centers on a single dose, with revaccination questions still being studied.
If you were vaccinated previously, ask your clinician whether a repeat dose is appropriate for you. The recommendations on revaccination have evolved, and this is an area where guidance may differ from what you read a year ago.
The Bottom Line on Choosing
If you are eligible and decide to get vaccinated, the most important step is getting one of these vaccines — not agonizing over which. All three reduce the risk of serious RSV illness in older adults.
Choose based on what your clinician recommends, what is available, and any specific factors like pregnancy eligibility. Do not choose based on claims that one is scientifically superior, because that claim is not backed by direct comparative trials.
Frequently Asked Questions
Which RSV vaccine is best for adults over 60?
No head-to-head trial has shown one of Arexvy, Abrysvo, or mResvia to be clearly better than the others in older adults. All three reduce the risk of serious RSV illness, so the choice usually depends on availability, eligibility, and your health profile.
Is mResvia better than Arexvy or Abrysvo because it is mRNA?
No, there is no direct evidence that the mRNA platform makes mResvia more effective than the protein-based vaccines in older adults. Each vaccine was tested separately, and cross-trial comparisons are not reliable.
Can I get the RSV vaccine if I am pregnant?
Abrysvo is the only one of these three approved for use during pregnancy, where the goal is to protect the newborn. Arexvy and mResvia are not approved for pregnancy.
Do I need an RSV vaccine every year?
Current guidance centers on a single dose, and revaccination recommendations are still being studied and have changed over time. Ask your clinician whether a repeat dose is appropriate for your situation.

